Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake

Eveline van de Stadt; Maqsood Yaqub; Alex Poot; Robert Schuit; Idris Bahce; E. Smit; Harry Hendrikse

Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake

Eveline van de Stadt, Maqsood Yaqub, Alex Poot, Robert Schuit, Idris Bahce, E. Smit, Harry Hendrikse

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Journal of nuclear medicine
Volume	60
Publication status	Published - 1 May 2019

Cite this

@article{389750da32994a94b4b7400e683e4518,

title = "Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake",

author = "{van de Stadt}, Eveline and Maqsood Yaqub and Alex Poot and Robert Schuit and Idris Bahce and E. Smit and Harry Hendrikse",

year = "2019",

month = may,

day = "1",

language = "English",

volume = "60",

journal = "Journal of nuclear medicine",

issn = "0161-5505",

publisher = "Society of Nuclear Medicine Inc.",

}

TY - JOUR

T1 - Can [F-18]afatinib PET/CT be used in identifying NSCLC patients with different EGFR mutational status: tracer quantification and assessment of tumor uptake

AU - van de Stadt, Eveline

AU - Yaqub, Maqsood

AU - Poot, Alex

AU - Schuit, Robert

AU - Bahce, Idris

AU - Smit, E.

AU - Hendrikse, Harry

PY - 2019/5/1

Y1 - 2019/5/1

M3 - Meeting Abstract

SN - 0161-5505

VL - 60

JO - Journal of nuclear medicine

JF - Journal of nuclear medicine

ER -